Critical Analysis: XOMA (NASDAQ:XOMAO) & PMV Pharmaceuticals (NASDAQ:PMVP)

PMV Pharmaceuticals (NASDAQ:PMVP) and XOMA (NASDAQ:XOMAO) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares PMV Pharmaceuticals and XOMA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-78.11%	-70.13%
XOMA	N/A	N/A	N/A

Valuation & Earnings

This table compares PMV Pharmaceuticals and XOMA”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74 million	($1.42)	-0.94
XOMA	$7.65 million	N/A	N/A	N/A	N/A

XOMA has higher revenue and earnings than PMV Pharmaceuticals.

Analyst Recommendations

This is a breakdown of current recommendations for PMV Pharmaceuticals and XOMA, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1	0	2	1	2.75
XOMA	0	0	0	0	0.00

PMV Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 200.75%. Given PMV Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe PMV Pharmaceuticals is more favorable than XOMA.

Insider and Institutional Ownership

90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 10.2% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

PMV Pharmaceuticals beats XOMA on 6 of the 9 factors compared between the two stocks.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.